Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Magnes Res. 2018 May 1;31(2):33-38. doi: 10.1684/mrh.2018.0440.
Depression is one of the major causes of disability worldwide. A proportion of adults with major depression fail to achieve remission with first-line treatment. Magnesium influences the neurotransmission involved in emotional processes, such as the serotonergic, noradrenergic, dopaminergic, GABAergic and glutamatergic systems. It has been reported that the mechanism of antidepressants' action is involved in the glutamatergic system. Theories about the role of magnesium ions in pathophysiology of major depressive disorder include blocking the glutamatergic N-methyl-D-aspartate receptor (NMDAR). Ketamine, NMDAR antagonist, was found to promote fast-acting antidepressant and antisuicidal effects. Magnesium and ketamine seem to be involved in key mechanisms of the major depression pathophysiology. The evidence in the paper discussed may indicate the synergistic interaction between magnesium and ketamine pharmacodynamic activity being of particular importance in mood disorders.
抑郁症是全球范围内导致残疾的主要原因之一。一部分患有重度抑郁症的成年人在一线治疗后未能缓解。镁会影响情绪处理过程中的神经递质传递，如 5-羟色胺能、去甲肾上腺素能、多巴胺能、γ-氨基丁酸能和谷氨酸能系统。据报道，抗抑郁药的作用机制涉及谷氨酸能系统。关于镁离子在重度抑郁症病理生理学中的作用的理论包括阻断谷氨酸 N-甲基-D-天冬氨酸受体（NMDAR）。已发现 NMDAR 拮抗剂氯胺酮可促进快速抗抑郁和抗自杀作用。镁和氯胺酮似乎参与了重度抑郁症病理生理学的关键机制。本文中讨论的证据可能表明镁和氯胺酮的药效学活性之间存在协同相互作用，这在情绪障碍中尤为重要。
